

**January 27, 2025**

BSE Limited PJ. Towers, Dalal Street Mumbai-400001 <b>Script Code: 532668</b>	National Stock Exchange of India Ltd, Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai -400051 <b>Script Code: AURIONPRO</b>
--	--

**Subject: Statement of deviation or variation in the use of proceeds of the issue Equity shares by way of preferential issue and Qualified Institutional Placement of the Company for the quarter ended 31<sup>st</sup> December, 2024**

Dear Sir/ Madam,

Pursuant to Regulation 32(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended read with SEBI Circular No. CIR/CFD/CMD1/162/2019 dated 24<sup>th</sup> December, 2019 and Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated 11<sup>th</sup> July, 2023, please find enclosed herewith a statement of deviation(s) or variation(s) in the utilization of funds raised through the Preferential issue and Qualified Institutional Placement for the quarter ended 31<sup>st</sup> December, 2024 in the prescribed format.

The aforesaid statement has been reviewed by the Audit Committee and taken on record by the Board at their respective meetings held on 27<sup>th</sup> January, 2025.

Kindly take the same on record.

Thanking you,

**For Aurionpro Solutions Limited**

  
**Nihad Kelkar**  
**Company Secretary**



<b>Statement of Deviation / Variation in utilisation of funds raised</b>	
<b>Name of listed entity</b>	Aurionpro Solutions Limited
<b>Mode of Fund Raising</b>	Preferential Issue (Equity Shares)
<b>Date of Raising Funds</b>	28 <sup>th</sup> March, 2024
<b>Amount Raised</b>	INR 2,00,00,01,025/-
<b>Report filed for Quarter ended</b>	31 <sup>st</sup> December, 2024
<b>Monitoring Agency</b>	Yes
<b>Monitoring Agency Name, if applicable</b>	CRISIL Ratings Limited
<b>Is there a Deviation / Variation in use of funds raised</b>	No
<b>If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders</b>	NA
<b>If Yes, Date of shareholder Approval</b>	NA
<b>Explanation for the Deviation / Variation</b>	NA
<b>Comments of the Audit Committee after review</b>	No comments
<b>Comments of the auditors, if any</b>	No comments
<b>Objects for which funds have been raised and where there has been a deviation, in the following table</b>	Strategic Acquisitions, Capital Expenditure for acquisition of office premises, Payments Business, General Corporate Purposes and Issue Expenses.  No deviation or variation in the utilisation of funds raised.



**Name of Signatory: Mr. Vipul Parmar**  
**Designation: Chief Financial Officer**



<b>Statement of Deviation / Variation in utilisation of funds raised</b>	
<b>Name of listed entity</b>	Aurionpro Solutions Limited
<b>Mode of Fund Raising</b>	Qualified Institutional Placement (Equity Shares)
<b>Date of Raising Funds</b>	08 <sup>th</sup> April, 2024
<b>Amount Raised</b>	INR 3,77,73,30,000/-
<b>Report filed for Quarter ended</b>	31 <sup>st</sup> December, 2024
<b>Monitoring Agency</b>	Yes
<b>Monitoring Agency Name, if applicable</b>	CRISIL Ratings Limited
<b>Is there a Deviation / Variation in use of funds raised</b>	No
<b>If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders</b>	NA
<b>If Yes, Date of shareholder Approval</b>	NA
<b>Explanation for the Deviation / Variation</b>	NA
<b>Comments of the Audit Committee after review</b>	No comments
<b>Comments of the auditors, if any</b>	No comments
<b>Objects for which funds have been raised and where there has been a deviation, in the following table</b>	Capital expenditure, the pre-payment and / or repayment (in full or in part) of debts, working capital requirements, strategic acquisitions, infusion of funds into our subsidiaries and joint ventures, general corporate purposes  No deviation or variation in the utilisation of funds raised



**Name of Signatory: Mr. Vipul Parmar**  
**Designation: Chief Financial Officer**

